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The First Simultaneous Pancreas, Renal 
Transplant in a Patient with HIV in Australia
Abstract
We	report	 the	first	 case	of	a	 simultaneous	pancreas	and	 renal	 transplantation,	
in	Australia,	 in	a	45	year	old	male	with	long	standing	human	immunodeficiency	




monitoring,	 successful	 outcomes	 were	 achieved	 during	 the	 peri	 and	 post	
transplantation	period,	with	excellent	pancreas	and	renal	graft	function	at	one	year.		
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Introduction
Recent	 experiences	 suggest	 that	 transplantation	 can	 be	 safely	
conducted	 in	 patients	 with	 human	 immunodeficiency	 virus	
(HIV)	infection.	Balancing	medication	interactions	between	anti-
retroviral	 therapy	 and	 immunosuppressive	 therapy	 remains	 a	
challenge.	Eight	cases	of	simultaneous	pancreas	and	kidney	(SPK)	
transplantation	 in	 HIV	 patients	 with	 type	 1	 diabetes	 mellitus	
(T1DM)	 have	 been	 reported	 with	 good	 outcomes	 [1-5].	 At	
transplantation,	all	patients	were	under	the	age	of	50	years,	with	
undetectable	 HIV	 RNA	 blood	 levels.	Most	 were	 on	 nucleoside	





A	 45	 year	 old	 male	 with	 HIV-1	 infection	 was	 referred	 to	 our	
facility	 from	 a	 regional	 area,	 for	 SPK	 transplantation.	 T1DM	
was	 diagnosed	 aged	 19	 years,	 complicated	 by	 nephropathy	















	 Twelve	 months	 later,	 at	 the	 time	 of	 transplantation,	 CD4	
count	 was	 518	 cells/mL,	 HIV	 viral	 load	 was	 undetectable	 and	
CMV	and	EBV	 IgG	were	negative.	 The	donor-recipient	was	0/6	
mismatched	 on	 HLA	 loci.	 Standard	 induction	 therapy	 included	
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Therapeutic	drug	monitoring	 (TDM)	allowed	gradual	escalation	
of	 the	 CI	 dose,	 with	 the	 aim	 to	 achieve	 adequate,	 yet	 safe,	
immunosuppression	 to	 optimise	 graft	 survival.	 Renal	 function	
fully	recovered	over	three	weeks,	allowing	gradual	escalation	to	
standard	doses	of	TDF	(Figure 1).
Insulin	 was	 no	 longer	 required	 post	 operatively.	 At	 discharge,	
proton	pump	inhibitor	was	ceased	and	enfuviritide	was	changed	
to	rilpivirine	(absorbed	in	acidic	environments).	TDF	was	replaced	
by	 Tenofovir	 alafenamide	 combined	with	 emtricitabine,	 a	 new	
agent	with	reduced	nephrotoxicity.	His	general	health	improved,	
despite	 several	 admissions	with	 psoas	 collection	 and	 a	 splenic	





The	 current	 case	 demonstrates	 that	 the	 presence	 of	 complex	
antiretroviral	drug	resistance	patterns,	requiring	thoughtful	anti-
retroviral	 treatment	 regimens,	 can	 be	 managed	 successfully	







Despite	 recommendations	 [6]	 against	 anti-retroviral	 treatment	
interruptions,	 the	 peri	 and	 post-operative	 approaches	 to	 anti-
retroviral	 therapy	 in	 SPK	 transplantation	 have	 varied.	 In	 one	
case,	anti-retrovirals	were	withheld,	without	virological	 failure,	
pre-operatively	and	seven	years	post	 [4].	 In	a	case	series,	anti-




The	 challenges	 faced	 in	 managing	 such	 patients	 are	 diverse.	
The	 primary	 challenge	 is	 that	 drug-drug	 interactions	 need	 to	
Tenofovir dose: 
300mg weekly 
300mg 3rd daily 
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be	 considered.	 PIs	 inhibit	 the	 metabolism	 of	 CI,	 necessitating	
lower	 doses	 of	 CIs	 [6].	 Conversely	 non-nucleoside	 reverse	
transcriptase	 inhibitors	 (NNRTI)	 can	 increase	 CI	 metabolism,	
necessitating	higher	doses	of	CIs	[6].	Despite	prior	PI	and	NNRTI	
use,	our	recipient	was	prescribed	TDF	(a	NRTI),	regardless	of	risk	
of	nephrotoxicity,	 as	 it	 has	minimal	 interactions	with	 immune-
suppressive	 drugs	 [6,7]	 and	 has	 antiviral	 activity	 despite	 his	
resistance	profile.	
The	 other	 agents	 used:	 integrase	 inhibitors	 (dolutegravir),	
maraviroc	 and	 enfuviritide	 exhibit	 minimal	 interactions	 with	
immunosuppressive	 regimes	 [6-8].	Enfuviritide,	 is	administered	
by	subcutaneous	injection,	limiting	long-term	use.	However,	once	
successfully	 transplanted	 an	 alternate	 regime	 was	 established	
safely.
Other	 challenges	 in	 managing	 patients	 requiring	 SPK	
transplantation	 include	 infective	 complications.	 The	 commonly	
reported	 infective	 complications	 included	 abscesses	 [1,2],	
urinary	tract	infections	[2,4],	CMV	viraemia	[1],	wound	infection,	
bacteraemia	 and	 pneumonia	 [4].	 Interestingly,	 one	 case	 was	
complicated	 by	 a	 psoas	 abscess,	 with	 good	 recovery,	 similar	
to	 our	 recipient	 [2].	 Other	 reported	 long	 term	 complications,	
included	 bleeding	 [2],	 haematoma	 [2],	 cholecystitis	 [2],	 mild	




with	 HIV	 must	 be	 considered.	 Simultaneous	 pancreas	 kidney	
transplantation	 is	 the	 treatment	 of	 choice	 for	 most	 patients	
with	 type	 1	 diabetes	mellitus	 and	 ESKD	because	 it	 saves	 lives,	
improves	 the	 quality	 of	 life	 and	 is	 cost-effective	 [9].	 Recently,	
the	advent	of	antiretroviral	 therapy,	HIV	positive	patients	with	
concurrent	 ESKD	 are	 expected	 to	 have	 similar	 expected	 graft	
survival	 as	 non-HIV	 patients	 [10].	 However,	 the	 proposals	 to	
transplant	HIV	positive	patients	have	also	raised	several	ethical	
concerns.	Apart	 from	the	 interactions	between	antiviral	agents	
and	 immunosuppression,	 the	 increased	 risk	 of	 acute	 rejection	
observed	in	HIV	transplant	recipients	also	poses	major	challenges	
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the	 inherent	 risk	 of	 opportunistic	 infections	 associated	 with	
immunosuppression	 such	 as	 T	 cell	 depleting	 agents	 for	 the	
management	of	acute	rejection.	
Nonetheless,	 this	 case	 supports	 that	 SPK	 transplantation	 is	
generally	safe,	with	 favourable	short-term	outcomes	 for	young	
patients	 with	 T1DM,	 renal	 failure	 and	 HIV,	 if	 a	 tailored	 and	
planned	program	is	used.	Future	studies	and	cases	should	expand	
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